Healthcare Archives

NexPoint Leads Series B Financing for Biotechnology Company Sapience Therapeutics

"HARRISON, N.Y., May 31, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on…

mmarschikJune 8, 2022

Healthcare NEWS PRESS RELEASE

NexPoint Participates in Series C Financing for Apnimed, a Clinical-stage Pharmaceutical Company Focused on Treating Sleep Disorders

"CAMBRIDGE, Mass. May 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral…

mmarschikMay 4, 2022

Form CRS | Important Risk Disclosures | Privacy Policy

Before investing in any of the NexPoint funds, you should carefully consider the fund’s investment objectives, risks, charges, and expenses. A copy of a fund’s prospectus, which contains this and other information, is available on the fund’s website or by calling the shareholder services at (844) 485-9167.

Please read the prospectus carefully before investing. This website is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein. An investment in any of the NexPoint offerings involves risk, and there can be no assurance that the investment objectives will be met. Past performance does not guarantee future results.

NexPoint Securities, Inc., Member FINRA/SIPC, is the distributor for NexPoint products.

Brokercheck.FINRA.org

8987

Healthcare

NexPoint Leads Series B Financing for Biotechnology Company Sapience Therapeutics

NexPoint Participates in Series C Financing for Apnimed, a Clinical-stage Pharmaceutical Company Focused on Treating Sleep Disorders

Follow NexPoint on LinkedIn

Contact Us

$2.7 Billion